Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelial function in clinical pulmonary hypertension.

R J Barst, S A Stalcup

    Chest
    |October 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension).

    International journal of cardiology·2015
    Same author

    Pulmonary arterial hypertension: a comparison between children and adults.

    The European respiratory journal·2011
    Same author

    A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

    Clinical pharmacology and therapeutics·2009
    Same author

    Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension.

    International journal of clinical practice. Supplement·2008
    Same author

    Delivery of intravenous treprostinil at low infusion rates using a miniaturized infusion pump in patients with pulmonary arterial hypertension.

    The journal of vascular access·2006
    Same author

    Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.

    The European respiratory journal·2006

    This study investigated vasoactive substances in children with pulmonary hypertension. Elevated norepinephrine and thromboxane levels suggest pulmonary release, potentially offering new therapeutic targets for this condition.

    Area of Science:

    • Cardiovascular Physiology
    • Pediatric Cardiology
    • Endothelial Biology

    Background:

    • The endothelium plays a crucial role in regulating pulmonary vascular tone through vasoactive substances.
    • Endothelial dysfunction can contribute to vasoconstriction and the development of pulmonary hypertension.
    • Understanding these mechanisms is vital for developing targeted therapies.

    Purpose of the Study:

    • To evaluate endothelial function in pediatric patients with pulmonary hypertension by measuring vasoactive substances.
    • To identify specific vasoactive substances contributing to pulmonary vasoconstriction in this patient group.
    • To explore potential new therapeutic strategies based on endothelial function.

    Main Methods:

    • Measurements of selected vasoactive substances were taken in 16 pediatric patients with pulmonary hypertension (idiopathic or congenital heart defect-related).

    Related Experiment Videos

  • Vasoactive substance levels were assessed before and during pharmacologic vasodilation attempts.
  • Concentrations were compared between the aorta and pulmonary artery to infer pulmonary release.

    • Main Results:

    • Elevated norepinephrine levels were observed in 60% of patients, with concentration gradients suggesting pulmonary release in some.
    • Increased thromboxane levels were found in 25% of patients, also indicating potential pulmonary release.
    • These findings highlight the role of specific vasoactive substances in pulmonary hypertension pathophysiology.

    Conclusions:

    • Endothelial dysfunction involving vasoactive substances contributes to pulmonary hypertension in children.
    • Pulmonary release of vasoconstrictors like norepinephrine and thromboxane is implicated.
    • Further understanding of endothelial metabolism may lead to more specific treatments for pediatric pulmonary hypertension.